Perspective Therapeutics (NYSE:CATX) Rating Increased to Strong-Buy at Brookline Capital Management

Perspective Therapeutics (NYSE:CATX) was upgraded by research analysts at Brookline Capital Management to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other analysts have also recently commented on CATX. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $16.00 target price on shares of Perspective Therapeutics in a report on Tuesday, January 14th. Oppenheimer decreased their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Finally, Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $24.00 to $5.00 in a report on Monday, November 25th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $15.13.

Perspective Therapeutics Trading Down 2.7 %

NYSE:CATX opened at $2.54 on Monday. The stock has a 50 day moving average of $3.20 and a two-hundred day moving average of $7.57. Perspective Therapeutics has a 12 month low of $2.32 and a 12 month high of $19.05.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC increased its position in shares of Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after purchasing an additional 5,370,392 shares during the last quarter. Millennium Management LLC purchased a new position in Perspective Therapeutics during the fourth quarter worth about $4,132,000. State Street Corp increased its position in shares of Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after acquiring an additional 1,192,812 shares during the last quarter. Octagon Capital Advisors LP raised its stake in shares of Perspective Therapeutics by 62.1% in the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock valued at $7,352,000 after acquiring an additional 882,528 shares during the period. Finally, Affinity Asset Advisors LLC lifted its holdings in shares of Perspective Therapeutics by 160.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock worth $4,147,000 after acquiring an additional 800,000 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.